Innovations In Clinical Neuroscience

JAN-FEB 2018

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: https://innovationscns.epubxp.com/i/935919

Contents of this Issue

Navigation

Page 21 of 53

R E V I E W 22 ICNS Innovations in Clinical Neuroscience • January–February 2018 • Volume 15 • Number 1–2 www.accessdata.fda.gov/drugsatfda_docs/ nda/2016/207318Orig1s000MedR.pdf. Accessed October 20, 2016. 29. Voss T, Bahr D, Jeffrey Cummings C, et al. Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. Parkinsonism Relat Disord. 2013;19:295–299. 30. Meltzer HY, Elkis H, Vanover K, et al. Pimavanserin, a selective serotonin (5-HT) 2A - inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res. 2012;141(2–3): 144–52. 31. Friedman JH. Pimavanserin for the treatment of Parkinson's disease psychosis. Expert Opin Pharmacother. 2013;14(14):1969–75. 32. Pollack P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomized, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004; 75:689–95. 33. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003;60(11):1756–1761. 34. Pollak P, Destee A, Tison F, et al. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet. 1999;353: 2041–2042. 35. Ondo WG, Tintner R, Voung KD, et al. Double- blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic- induced hallucinations in Parkinson's disease. Mov Disord. 2005;20(8):958–963. 36. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord. 2007;22(3):313–318. 37. Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat. 2009;5:327–332. 38. Clozapine REMS. Clozapine REMS Program website. https://www.clozapinerems.com. Accessed October 20, 2016. 39. Love RC, Kelly DL, Feudenreich O, et al. Clozapine underutilization: addressing the barriers. National Association of State Mental Health Program Directors webite. September 2016. https://www.nasmhpd.org/sites/ default/files/Assessment%201_Clozapine%20 Underutilization.pdf. Accessed January 19, 2018. 40. Merims D, Balas M, Peretz C, et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol. 2006;29(6):331–337. 41. Friedman J, Lannon M, Comella C, et al. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999; 340:757–763 42. Lexi-Drugs. Lexicomp. Wolters Kluwer Helaht, Inc. website. Riverwoods, IL. http://online.lexi. com. Accessed September 29, 2016. 43. Redbook online. Thompson Readers. www. redbook.com. Accessed September 29, 2016. 44. Clozaril (clozapine) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015. 45. Seroquel (quetiapine) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2013. ICNS

Articles in this issue

Links on this page

Archives of this issue

view archives of Innovations In Clinical Neuroscience - JAN-FEB 2018